TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
종목 코드 TELA
회사 이름TELA Bio Inc
상장일Nov 08, 2019
CEOMr. Antony Koblish
직원 수209
유형Ordinary Share
회계 연도 종료Nov 08
주소1 Great Valley Parkway, Suite 24
도시MALVERN
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호19355
전화14843202930
웹사이트https://www.telabio.com/
종목 코드 TELA
상장일Nov 08, 2019
CEOMr. Antony Koblish
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음